CLARITIN LIQUID CAPSULES

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

LORATADINE

可用日期:

BAYER INC

ATC代码:

R06AX13

INN（国际名称）:

LORATADINE

剂量:

10MG

药物剂型:

CAPSULE

组成:

LORATADINE 10MG

给药途径:

ORAL

每包单位数:

24/36/84

处方类型:

OTC

治疗领域:

SECOND GENERATION ANTIHISTAMINES

產品總結:

Active ingredient group (AIG) number: 0120416001; AHFS:

授权状态:

APPROVED

授权日期:

2014-12-05

产品特点

PRODUCT MONOGRAPH
CLARITIN
® LIQUID CAPSULES LORATADINE CAPSULES, 10 MG
HISTAMINE H
1
RECEPTOR ANTAGONIST
Bayer Inc.
DATE OF PREPARATION:
2920 Matheson Blvd. E
May 10
th
, 2019
Mississauga, ON
L4W 5R6
Control #: 225631
® TM see www.bayer.ca/tm-mc
_ _
_CLARITIN LIQUID CAPSULES _
_Page 2 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
………………………………….…...
3
SUMMARY PRODUCT INFORMATION
...........................................................................
3
INDICATIONS AND CLINICAL
USE.................................................................................
3
CONTRAINDICATIONS
......................................................................................................
3
WARNINGS AND PRECAUTIONS
....................................................................................
3
ADVERSE REACTIONS
......................................................................................................
4
DRUG INTERACTIONS
.......................................................................................................
6
DOSAGE AND ADMINISTRATION
...................................................................................
7
OVERDOSAGE
.....................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 7
STORAGE AND STABILITY
..............................................................................................
8
SPECIAL HANDLING INSTRUCTIONS
............................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 9
PART II: SCIENTIFIC INFORMATION
…………………………………………………….
. 10
PHARMACEUTICAL INFORMATION
............................................................................
10
CLINICAL
TRIALS...........................................................